AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04694898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SURE intervention
Description: The SURE package includes: 1) promoting diversified agriculture; 2) promoting infant and young child feeding practices; 3) women empowerment in decision making related to agriculture, food and health; and 4) enhanced food security and Water, Sanitation and Hygiene (WASH) practices.
Study NCT00235820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40 mg every other week following an 80 mg dose
Study NCT00235820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: MTX 7.5 to 25 mg once weekly
Study NCT00235820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo adalimumab, placebo MTX
Description: placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)
Study NCT00880035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MP3 music program listening
Description: 3 days with two 1 hour periods of headset music listening (1 day on, 1 day wash-out, 1 day off)
Study NCT01481389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Theobromine
Description: 200 ml drink with added theobromine (no cocoa added)
Study NCT01481389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa
Description: 200 ml drink with cocoa (no theobromine added)
Study NCT01481389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa and theobromine
Description: 200 ml drink with added cocoa and theobromine
Study NCT01481389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 ml drink (no added theobromine or cocoa)
Study NCT00928564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal block
Description: 8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
Study NCT00928564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5ml of saline at each block site.
Study NCT02090153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40\~60mg bid，d1\~7 q2W
Study NCT02090153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: LV is given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest.
Study NCT02477579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaCross
Description: The NovaCross™ is a guidewire positioning and support microcatheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment, both at its distal tip.
Study NCT00084266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linezolid (Zyvox)
Description: Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
Study NCT00084266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
Study NCT03840850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Risk Communication for People with Type 2 Diabetes
Description: The risk communication intervention consists of communicating the impact of being poorly controlled on two types of outcome: (1) absolute 10-year risk of experiencing a cardiovascular event, i.e. heart attack or stroke (10-year CV risk); (2) life expectancy. These personalized risk estimates are calculated based on the UKPDS outcomes model (version 2), which is a prognostic model of reference in the area of Type 2 diabetes.
Study NCT04556643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: The main components of breathing exercises during training will be as follows (A) First, fill your stomach and then your lungs with air while breathing in; (B) Feel the expansion in the stomach; (C) Make sure the muscles from your stomach to your knee are relaxed, as if you are urinating while breathing out; (D) When there is pain, perform deep abdominal breathing exercises, and take a deep breath in and hold as much as you can; (E) Try to push the baby downward; (F) You can do it by holding your breath or breathing out quite slowly from your mouth; (G) The most important point in this stage is that you should not fill up the stomach with air, and you should push downward to deliver the baby; (H) You should continue the pushing until the pain is relieved
Study NCT01096342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinaciclib
Description: Given IV
Study NCT01096342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04206592 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oropharyngeal leak pressure during pneumoperitoneum.
Description: Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 litres/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.
Study NCT00557388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein/Amino Acids
Description: Casein Whey Leucine
Study NCT00557388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The physical exercise protocol will consist of low intensity cycling and light resistance-type exercise; after 5 minutes of self-paced cycling, subjects will perform 6 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, The Netherlands) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV, Rotterdam, The Netherlands). The first 2 sets of both resistance exercises will be performed at 40% of the subjects' 1RM. Sets 3-4, and 5-6 will be performed at 55% and 75% of 1RM, respectively, with 2 minutes rest intervals between sets.
Study NCT01419353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate
Description: 2 mg P.O / day for 1-6 days.
Study NCT01419353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate
Description: 2 mg P.O / day for 1-6 days.
Study NCT02797210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous theta-burst stimulation
Study NCT01034293 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low feeding frequency (3x)
Description: 3 meals a day
Study NCT01034293 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High feeding frequency (14x)
Description: 14 meals a day
Study NCT02014155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects.
Study NCT02014155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
Study NCT03513172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)
Description: The rapid hypotensive effects of topical alpha2-agonists such as brimonidine tartrate on decreasing aqueous production and increasing uveoscleral outflow, in addition to their neuroprotective properties, make them an attractive option for prophylactic treatment of post-injection IOP spikes.
Study NCT02997488 — intervention group
Intervention type: DEVICE
Intervention: Pentax Airwayscope
Description: intubation using Pentax Airwayscope
Study NCT02997488 — intervention group
Intervention type: DEVICE
Intervention: McGrath Videolaryngoscope
Description: intubation using McGrath Videolaryngoscope
Study NCT00567268 — intervention group
Intervention type: DRUG
Intervention: Gabapentin
Description: GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan.~Dosage, frequency: According to Japanese LPD, Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).~Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration.
Study NCT00470210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
Description: Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
Study NCT00470210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (Copegus®) 1600 mg/day
Description: Ribavirin (Copegus®) 1600 mg/day
Study NCT00470210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin β (450 UI/kg/week)
Description: Epoetin β (450 UI/kg/week)
Study NCT03255837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS, a form of non-invasive brain stimulation) on the left dorsolateral prefrontal cortex (DLPFC)
Study NCT03255837 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS, a form of non-invasive brain stimulation) on the left dorsolateral prefrontal cortex (DLPFC)
Study NCT01438021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01438021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given intraventricularly
Study NCT00152139 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic Stem Cell Transplantation
Description: An infusion of HLA matched unrelated bone marrow or peripheral blood stem cells.
Study NCT00152139 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy and antibodies
Description: Participants received a standard conditioning regimen consisting of total body irradiation, cyclophosphamide, thiotepa and ATG. GVHD prophylaxis consisted of cyclosporine and Methotrexate.
Study NCT01685190 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prostate alone IMRT
Description: Participants will receive standard prostate IMRT of 74Gy in 37 fractions delivered over 7.5 weeks.
Study NCT01685190 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate and pelvis IMRT
Description: Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
Study NCT00149422 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NT-proBNP measurements
Study NCT00149422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NT-proBNP measurements
Study NCT01889056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epoetin beta)
Study NCT01889056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride solution
Study NCT02952001 — intervention group
Intervention type: DRUG
Intervention: 4 mg CLS-TA Suprachoriodal Injection
Description: This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
Study NCT02952001 — intervention group
Intervention type: DRUG
Intervention: Sham procedure
Description: This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
Study NCT00720655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Fatty fish at least 4 meals per week.
Study NCT00720655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Lean fish at least 4 meals per week.
Study NCT00720655 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary intervention
Description: Control diet with lean meat and chicken.
Study NCT01212250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol with a maximum of 6.25 BD.
Study NCT01212250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.
Study NCT05385133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer guided condylar position
Description: post-osteotomy condylar position was performed using patient specific surgical guides and pre-bent plates
Study NCT05385133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual condylar position
Description: post-osteotomy condylar position was performed using the conventional manual method
Study NCT01521897 — intervention group
Intervention type: BIOLOGICAL
Intervention: 7-valent vaccine injection
Description: For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose.
Study NCT02261038 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kanekasu radiographs
Description: No interventions are performed here. All patients undergo CT and special radiographs of the knee to assess femoral TKA rotation.
Study NCT02616666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets, and FORXIGA™ should be prescribed according to the instructions in the SmPC and current practice, including up-titration (if considered appropriate by the investigator). Dapagliflozin will be given in combination with metformin.
Study NCT02616666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The comparator arm consists of SOC. The SOC arm can be sulphonylurea (SU) or non-SU treatments. SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin. The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy. Other SGLT-2 inhibitors are excluded. All these treatments are approved in the UK for use in this patient population.
Study NCT01782118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Study NCT01782118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus GG
Study NCT02544217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH176
Study NCT02544217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT04576143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: i.v. 90 mg/m2
Study NCT04576143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: i.v. 90 mg/m2
Study NCT04576143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamid
Description: i.v. 600 mg/m2
Study NCT04576143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: i.v. 600 mg/m2
Study NCT04576143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: i.v. 100 mg/m2
Study NCT04576143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: i.v. 175 mg/m2
Study NCT05165147 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04298463 — intervention group
Intervention type: DRUG
Intervention: Xydalba
Description: Drugs were administered i.v.
Study NCT04298463 — intervention group
Intervention type: DRUG
Intervention: vancomycin, teicoplanin or daptomycin
Description: Drugs were administered i.v.
Study NCT00638612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdV-tk
Description: Four dose levels of AdV-tk with a fixed dose level of valacyclovir are evaluated independently in the two arms of the study due to differences in the concomitant standard of care treatments. The first AdV-tk course is given prior to surgery or radiation by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery in Arm A or same as the first injection in Arm B again followed by 14 days of valacyclovir. The AdV-tk dose levels are: Level 1= 3x10e10 vector particles (vp), Level 2= 1x10e11 vp, Level 3= 3x10e11 vp, Level 4= 1x10e12 vp
Study NCT00638612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.
Study NCT01249937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranibizumab
Description: Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
Study NCT01249937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
Study NCT01249937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Sub-tenon injection of 40mg/mL dosage at months 0 and 2 with follow up for a total of 6 months.
Study NCT01685710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTN patch
Study NCT01685710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: This arm will be a placebo patch to the active drug patch to blind the trial.
Study NCT02415465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Adductor Canal Block
Description: Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr)
Study NCT02415465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General
Description: General Intraoperative Anesthesia
Study NCT02415465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus)
Study NCT02415465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal
Description: Spinal Intraoperative Anesthesia
Study NCT00774865 — intervention group
Intervention type: PROCEDURE
Intervention: MIBI and CTA
Description: Rest and Stress MIBI and CT Angiography
Study NCT00135759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: low dose naltrexone in addition to daily methadone taper
Study NCT00135759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 1 capsule/day for 6 days
Study NCT00135759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: 0.125 mg capsule/day for 6 days
Study NCT00135759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: 0.250 mg capsule/day for 6 days
Study NCT03856658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR)
Description: Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.